Health News

Every 13 minutes a woman loses her battle with breast cancer and in 2009 alone more than 27,000 men died from prostate cancer. These powerful statistics continue to fuel research and new developments. With tens of millions of dollars in financial support from the National Cancer Institute and the U.S. Department of Defense, scientists have identified when estrogen metabolism is out of balance it can start the process leading to breast cell mutations.

Read more

Filed under: Pharmacy News
Tags: Breast Cancer, cancer, Pharmacy, Prostate Cancer

Related posts

• PARP inhibitors may be effective in men with prostate cancer due to BRCA2 alteration: Researchers (0)
  The way prostate cancer develops in men who have an altered 'breast cancer gene' is the same route by which breast cancer develops in women with the same mutation, reveals a study published in PLoS Genetics today (Thursday). Read more [tags] Pharmacy News [/tags]
  
  
• Medicare to cover 2 expensive cancer drugs (0)
  Medicare confirmed on Thursday that it would continue to pay for two expensive cancer drugs that had been at the center of debate — Avastin from Genentech for breast cancer and Provenge from Dendreon for prostate cancer. Read more [tags] Pharmacy News [/tags]
  
  
• Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy (0)
  Harbor BioSciences, Inc. today announced that the company has received a notice of allowance from the United States Patent Office of patent claims covering the use of its lead product candidate Apoptone®. The patent claims cover the use of Apoptone to treat prostate cancer, breast cancer and benign prostatic hypertrophy. Apoptone (HE3235) is a novel [...]
  
  
• FDA Okays Denosumab for Cancer-Induced Bone Loss (0)
  WASHINGTON (MedPage Today) -- The FDA has approved the osteoporosis drug denosumab (Prolia) as a treatment for bone loss in women with breast cancer and men with non-metastatic prostate cancer. Read more [tags] Pharmacy News [/tags]
  
  
• Amgen’s Prolia receives FDA approval for new indications to treat cancer patients (0)
  Amgen today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for Prolia® (denosumab) as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer and as a treatment to increase bone mass in men at high risk for fracture [...]